A new study published in Otolaryngology–Head and Neck Surgery reveals that glucagon-like peptide-1 receptor agonists (GLP-1RAs)—a class of medications primarily used for weight loss and diabetes ...
Use of GLP-1 RAs is associated with reduced postoperative revision following FESS for up to 5 years among patients with CRSwNP and obesity.
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending dupilumab as an ...
The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued final draft guidance ...
Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...
Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...
SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by ...
The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals and Sanofi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results